ENDRA Life Sciences Inc.
NDRA
$3.98
$0.529915.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.63M | 4.85M | 5.63M | 5.71M | 5.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.82M | 7.98M | 9.60M | 10.36M | 10.52M |
| Operating Income | -10.82M | -7.98M | -9.60M | -10.36M | -10.52M |
| Income Before Tax | -11.51M | -8.82M | -9.57M | -9.89M | -10.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.51 | -8.82 | -9.57 | -9.89 | -10.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.51M | -8.82M | -9.57M | -9.89M | -10.06M |
| EBIT | -10.82M | -7.98M | -9.60M | -10.36M | -10.52M |
| EBITDA | -10.77M | -7.92M | -9.52M | -10.26M | -10.40M |
| EPS Basic | -160.21 | -152.52 | -142.99 | -- | -- |
| Normalized Basic EPS | -100.13 | -95.33 | -89.37 | -- | -- |
| EPS Diluted | -160.21 | -152.52 | -142.99 | -- | -- |
| Normalized Diluted EPS | -100.13 | -95.33 | -89.37 | -- | -- |
| Average Basic Shares Outstanding | 802.00K | 262.40K | 15.60K | -- | -- |
| Average Diluted Shares Outstanding | 802.00K | 262.40K | 15.60K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |